STOCK TITAN

Hoth Therapeutics to Attend EF Hutton Annual Global Conference, May 15, 2024

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences

Hoth Therapeutics, Inc. (HOTH) will have its CEO attend the EF Hutton Annual Global Conference in New York, NY. The conference provides networking opportunities and a platform to showcase the company's biopharmaceutical endeavors.

Il CEO di Hoth Therapeutics, Inc. (HOTH) parteciperà alla Conferenza Globale Annuale EF Hutton a New York, NY. La conferenza offre opportunità di networking e una piattaforma per presentare le iniziative biofarmaceutiche dell'azienda.
El CEO de Hoth Therapeutics, Inc. (HOTH) asistirá a la Conferencia Global Anual de EF Hutton en Nueva York, NY. La conferencia brinda oportunidades de networking y una plataforma para exhibir los esfuerzos biofarmacéuticos de la compañía.
Hoth Therapeutics, Inc.(HOTH)의 CEO가 뉴욕, NY에서 열리는 EF Hutton 연례 글로벌 컨퍼런스에 참석할 예정입니다. 이 컨퍼런스는 네트워킹 기회를 제공하며 회사의 바이오제약 활동을 소개할 수 있는 플랫폼을 제공합니다.
Le PDG de Hoth Therapeutics, Inc. (HOTH) assistera à la Conférence Globale Annuelle EF Hutton à New York, NY. La conférence offre des opportunités de réseautage et une plateforme pour mettre en avant les efforts biopharmaceutiques de l'entreprise.
Der CEO von Hoth Therapeutics, Inc. (HOTH) wird an der jährlichen globalen Konferenz von EF Hutton in New York, NY teilnehmen. Die Konferenz bietet Netzwerkmöglichkeiten und eine Plattform, um die biopharmazeutischen Unternehmungen des Unternehmens zu präsentieren.
Positive
  • None.
Negative
  • None.

NEW YORK, May 1, 2024 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced that Robb Knie, Chief Executive Officer, is scheduled to attend the EF Hutton Annual Global Conference in New York, NY. 

To learn more about the EF Hutton Annual Global Conference please visit https://efhutton.com/conference/.

About Hoth Therapeutics, Inc.
Hoth Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing innovative, impactful, and ground-breaking treatments with a goal to improve patient quality of life. We are a catalyst in early-stage pharmaceutical research and development, elevating drugs from the bench to pre-clinical and clinical testing. Utilizing a patient-centric approach, we collaborate and partner with a team of scientists, clinicians, and key opinion leaders to seek out and investigate therapeutics that hold immense potential to create breakthroughs and diversify treatment options. To learn more, please visit https://ir.hoththerapeutics.com/ .

Investor Contact:
LR Advisors LLC 
Email: investorrelations@hoththerapeutics.com
www.hoththerapeutics.com
Phone: (678) 570-6791

 

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/hoth-therapeutics-to-attend-ef-hutton-annual-global-conference-may-15-2024-302132803.html

SOURCE Hoth Therapeutics, Inc.

FAQ

When is the EF Hutton Annual Global Conference?

The EF Hutton Annual Global Conference is scheduled for May 15, 2024.

Who will attend the EF Hutton Annual Global Conference on behalf of Hoth Therapeutics?

Robb Knie, the Chief Executive Officer of Hoth Therapeutics, will be attending the EF Hutton Annual Global Conference.

Where is the EF Hutton Annual Global Conference taking place?

The conference will be held in New York, NY.

What is the purpose of Hoth Therapeutics attending the EF Hutton Annual Global Conference?

The attendance aims to provide networking opportunities and showcase the company's biopharmaceutical initiatives.

How can I learn more about the EF Hutton Annual Global Conference?

To learn more about the conference, visit https://efhutton.com/conference/.

Hoth Therapeutics, Inc.

NASDAQ:HOTH

HOTH Rankings

HOTH Latest News

HOTH Stock Data

5.77M
4.10M
1.62%
6.98%
4.95%
Medicinal and Botanical Manufacturing
Manufacturing
Link
United States of America
NEW YORK

About HOTH

hoth therapeutics, inc., a biopharmaceutical company, focuses on developing therapies for dermatological disorders. the company focuses on therapies for patients suffering from indications, including eczema, chronic wounds, psoriasis, asthma, and acne. it intends to use the biolexa platform to develop two topical cream products that treat eczema and reduces post-procedure infections for patients undergoing aesthetic dermatology procedures. the company has license agreements with the george washington university; the university of maryland baltimore; isoprene pharmaceuticals, inc.; the north carolina state university; chelexa biosciences, inc.; and the university of cincinnati. it also has a partnership agreement with zyl㶠therapeutics inc. co-develop a new topical treatment for patients with cutaneous lupus erythematosu, a chronic autoimmune disease that affects the skin and is associated with a significant burden on patient quality of life. hoth therapeutics has research collaboratio